All In Biotech

Drug Trial Radar · NCT04227600

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Phase I/II Study of JR-171 ㏌ Patients With Mucopolysaccharidosis Type I

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Sep 1, 2020

Primary completion

Aug 2, 2022

Study completion Aug 2, 2022

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).

Conditions

  • Mucopolysaccharidosis I

Interventions

  • JR-171 (lepunafusp alfa)Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: Time of the first dose of JR-171 until the last visit (Week 5 for Part 1/ Week 13 for Part 2).

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Instituto de Genética e Erros Inatos do Metabolismo - IGEIM

    São Paulo, Brazil

  • Fukuoka Children's Hospital

    Fukuoka, Japan

  • Kochi Medical School Hospital

    Nankoku, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.